Latest Breaking News On - Intravenous atezolizumab - Page 1 : comparemela.com

Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.

Federico cappuzzoEli lillyEuropean lung cancer congressEuropean commissionBristol myers squibbIllumina incMirati therapeutics incBayer agRoche ltdTakeda pharmaceuticalsAmgen incLung cancerMedical oncologyAzienda unitSanitaria localeMirati therapeutics